China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

Stock Information for China Pharma Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About China Pharma Holdings Inc.

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville
China Pharma Announces the Entry of "At-The-Market" Equity Offering
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.